Cargando…

Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites

BACKGROUND: Cytology remains the gold standard for the detection of malignant cells in ascites. However, its sensitivity is limited. The aim of this study was to evaluate DNA methylation biomarkers for the differential diagnosis of benign (ascites in patients without malignancy), malignant (ascites...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Maria, Pützer, Svenja, Gevensleben, Heidrun, Meller, Sebastian, Kristiansen, Glen, Dietrich, Dimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4774089/
https://www.ncbi.nlm.nih.gov/pubmed/26937257
http://dx.doi.org/10.1186/s13148-016-0192-7
_version_ 1782418853549047808
author Jung, Maria
Pützer, Svenja
Gevensleben, Heidrun
Meller, Sebastian
Kristiansen, Glen
Dietrich, Dimo
author_facet Jung, Maria
Pützer, Svenja
Gevensleben, Heidrun
Meller, Sebastian
Kristiansen, Glen
Dietrich, Dimo
author_sort Jung, Maria
collection PubMed
description BACKGROUND: Cytology remains the gold standard for the detection of malignant cells in ascites. However, its sensitivity is limited. The aim of this study was to evaluate DNA methylation biomarkers for the differential diagnosis of benign (ascites in patients without malignancy), malignant (ascites in cancer patients directly caused by malignancy), and paramalignant (ascites in cancer patients caused by comorbidities but not by malignancy) ascites. METHODS: A cohort of 283 patients (134 cancer patients, 149 patients with benign diseases) presenting with ascites was prospectively enrolled. Ascites was evaluated by means of cytopathological investigation and DNA methylation of SHOX2 and SEPT9 in the cell-free and cellular fraction. DNA methylation in bisulfite-converted DNA was determined using quantitative methylation specific real-time PCR. Cytopathological and DNA methylation results were evaluated with regard to diagnosis and overall survival (OS). RESULTS: Patients with positive DNA methylation had a poor overall survival compared to methylation-negative patients (hazard ratio: HR = 1.97, p = 0.001). In multivariate survival analysis, DNA methylation was an independent prognostic parameter (p = 0.003) together with age (HR = 1.03, p < 0.001) and the presence of malignant disease (HR = 1.87, p < 0.001). The combination of methylation with cytopathological analyses led to a 42 % increase in the detection rate of malignant ascites, resulting in 37 % positively diagnosed cancer patients and a specificity of 97 %. Among cancer patients, patients with DNA methylation-positive ascites showed an adverse clinical course (HR = 1.63, p = 0.039). CONCLUSIONS: DNA methylation testing adds diagnostic and prognostic information and might constitute an effective ancillary method for the differential diagnosis of malignant, paramalignant, and benign ascites. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13148-016-0192-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4774089
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47740892016-03-03 Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites Jung, Maria Pützer, Svenja Gevensleben, Heidrun Meller, Sebastian Kristiansen, Glen Dietrich, Dimo Clin Epigenetics Research BACKGROUND: Cytology remains the gold standard for the detection of malignant cells in ascites. However, its sensitivity is limited. The aim of this study was to evaluate DNA methylation biomarkers for the differential diagnosis of benign (ascites in patients without malignancy), malignant (ascites in cancer patients directly caused by malignancy), and paramalignant (ascites in cancer patients caused by comorbidities but not by malignancy) ascites. METHODS: A cohort of 283 patients (134 cancer patients, 149 patients with benign diseases) presenting with ascites was prospectively enrolled. Ascites was evaluated by means of cytopathological investigation and DNA methylation of SHOX2 and SEPT9 in the cell-free and cellular fraction. DNA methylation in bisulfite-converted DNA was determined using quantitative methylation specific real-time PCR. Cytopathological and DNA methylation results were evaluated with regard to diagnosis and overall survival (OS). RESULTS: Patients with positive DNA methylation had a poor overall survival compared to methylation-negative patients (hazard ratio: HR = 1.97, p = 0.001). In multivariate survival analysis, DNA methylation was an independent prognostic parameter (p = 0.003) together with age (HR = 1.03, p < 0.001) and the presence of malignant disease (HR = 1.87, p < 0.001). The combination of methylation with cytopathological analyses led to a 42 % increase in the detection rate of malignant ascites, resulting in 37 % positively diagnosed cancer patients and a specificity of 97 %. Among cancer patients, patients with DNA methylation-positive ascites showed an adverse clinical course (HR = 1.63, p = 0.039). CONCLUSIONS: DNA methylation testing adds diagnostic and prognostic information and might constitute an effective ancillary method for the differential diagnosis of malignant, paramalignant, and benign ascites. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13148-016-0192-7) contains supplementary material, which is available to authorized users. BioMed Central 2016-03-01 /pmc/articles/PMC4774089/ /pubmed/26937257 http://dx.doi.org/10.1186/s13148-016-0192-7 Text en © Jung et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Jung, Maria
Pützer, Svenja
Gevensleben, Heidrun
Meller, Sebastian
Kristiansen, Glen
Dietrich, Dimo
Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites
title Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites
title_full Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites
title_fullStr Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites
title_full_unstemmed Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites
title_short Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites
title_sort diagnostic and prognostic value of shox2 and sept9 dna methylation and cytology in benign, paramalignant, and malignant ascites
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4774089/
https://www.ncbi.nlm.nih.gov/pubmed/26937257
http://dx.doi.org/10.1186/s13148-016-0192-7
work_keys_str_mv AT jungmaria diagnosticandprognosticvalueofshox2andsept9dnamethylationandcytologyinbenignparamalignantandmalignantascites
AT putzersvenja diagnosticandprognosticvalueofshox2andsept9dnamethylationandcytologyinbenignparamalignantandmalignantascites
AT gevenslebenheidrun diagnosticandprognosticvalueofshox2andsept9dnamethylationandcytologyinbenignparamalignantandmalignantascites
AT mellersebastian diagnosticandprognosticvalueofshox2andsept9dnamethylationandcytologyinbenignparamalignantandmalignantascites
AT kristiansenglen diagnosticandprognosticvalueofshox2andsept9dnamethylationandcytologyinbenignparamalignantandmalignantascites
AT dietrichdimo diagnosticandprognosticvalueofshox2andsept9dnamethylationandcytologyinbenignparamalignantandmalignantascites